University of California

Signal Pharmaceuticals, Inc.

Mehran F Moghaddam

Bruce D Hammock

Paul E Erdman

Yoshitaka Satoh

Mark A Nagy

Jan Elsner

Christophe H Morisseau

Stephen Norris

Marianne Sloss

Brydon L Bennett

Jayashree Tikhe

Robert Hilgraf

David A Paisner

Jiang Zheng

Won Hyung Yoon

Meg McCarrick

Babak Borhan

Laurie Ann LeBrun

David F Grant

Marlene F Sisemore

Jessica F Greene

James Fergusson

Jeffrey M Cheek

Kazuhiko Matoba

James Sanborn

Maria Mercedes Delgado

William J Romanow

Kazuhiko Motoba

The invention provides compounds that inhibit epoxide hydrolase in therapeutic applications for treating hypertension. A preferred class of compounds for practicing the invention have the structure shown by Formula 1 wherein Z is oxygen or sulfur, W is carbon phosphorous or sulfur, X and Y is each independently nitrogen, oxygen, or sulfur, and X can further be carbon, at least one of R-Ris hydrogen, Ris hydrogen when X is nitrogen but is not present when X is sulfur or oxygen, Ris hydrogen when Y is nitrogen but is not present when Y is sulfur or oxygen, Rand Ris each independently C-Csubstituted or unsubstituted alkyl, cycloalkyl, aryl, acyl, or heterocyclic.

Inhibitors of epoxide hydrolases for the treatment of inflammation

The present invention provides methods of treating inflammatory diseases mediated by poly-unsaturated lipid metabolites by inhibiting epoxide hydrolase, methods for assaying or screening the epoxide hydrolase inhibitors for inhibitory specificity and for toxicity, and novel biologically active tetrahydrofuran diols of arachidonic acid, including antibodies thereto.

Epoxide hydrolase inhibitor methods

The present invention provides novel biologically active tetrahydrofuran diols of arachidonic acid.

Dihydroxy-oxy-eicosadienoates

Growing community of inventors

San Diego, CA, United States of America

Mehran F Moghaddam